← Back to Clinical Trials
Recruiting NCT06853652

NCT06853652 Protein Requirements After Bariatric Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06853652
Status Recruiting
Phase
Sponsor Universitaire Ziekenhuizen KU Leuven
Condition Obesity and Overweight
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2025-03-17
Primary Completion 2026-06-25

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2025-03-17 with a primary completion date of 2026-06-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study investigates protein requirements at least 1 year after gastric bypass surgery in adult males, to investigate whether protein requirements are elevated compared to protein requiremens for the general populaiotn. The main study outcome is the estimated average protein requirements for the study populaiton.

Eligibility Criteria

Inclusion Criteria: 1. Male aged 18 - 65 years, 2. Primary RYGB surgery one to ten years before, 3. Weight stable within 5% over the last 3 months, 4. Normotensive or blood pressure controlled with antihypertensive therapy, 5. Provision of informed consent to participate, Exclusion Criteria: 1. Current diagnosis of cancer or active cancer in the preceding 1 year, 2. Any chronic or acute disease which is known to affect amino acid absorption, metabolism, or requirements, 3. Weight loss after bariatric surgery of less than 40% of excess weight, 4. Weight regain after bariatric surgery greater than 20% of nadir weight, 5. Diabetes mellitus defined as a fasting plasma glucose concentration ≥ 7.0 mmol, or HbA1c less than 6.5%, or medical treatment for diabetes.

Contact & Investigator

Central Contact

Gabriel Eksteen, MSc

✉ gabrieljohannes.eksteen@kuleuven.be

📞 +32 16345708

Principal Investigator

Bart Van der Schueren, MD PhD

PRINCIPAL INVESTIGATOR

KU Leuven

Frequently Asked Questions

Who can join the NCT06853652 clinical trial?

This trial is open to male participants only, aged 18 Years or older, up to 65 Years, studying Obesity and Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06853652 currently recruiting?

Yes, NCT06853652 is actively recruiting participants. Contact the research team at gabrieljohannes.eksteen@kuleuven.be for enrollment information.

Where is the NCT06853652 trial being conducted?

This trial is being conducted at Leuven, Belgium.

Who is sponsoring the NCT06853652 clinical trial?

NCT06853652 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Bart Van der Schueren, MD PhD at KU Leuven. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology